-
Archives
- December 2017
- June 2017
- May 2017
- February 2017
- November 2016
- October 2016
- September 2016
- July 2016
- April 2016
- March 2016
- December 2015
- August 2015
- April 2015
- February 2015
- January 2015
- December 2014
- November 2014
- September 2014
- August 2014
- July 2014
- May 2014
- January 2014
- December 2013
- November 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
-
Meta
Category Archives: Prostate Cancer
A Second Look at the European Randomised Study OfScreening For Prostate Cancer
Tweet Last week, The Lancet published 13-year follow-up results from the European Randomised study of Screening for Prostate Cancer (ERSPC), an international trial of PSA testing in seven countries (the Netherlands, Belgium, Sweden, Finland, Italy, Spain, and Switzerland). (Unfortunately, the … Continue reading
Posted in Prostate Cancer
Tagged clinical trials, ERSPC, harms, PSA, screening
Comments Off on A Second Look at the European Randomised Study OfScreening For Prostate Cancer
With Prostate-Specific Antigen (PSA) Screening Questioned, Why Not Hurl Out the Next Unproven Prostate Tests?
Tweet The headline in the New York Times story this morning, “New Prostate Cancer Tests Could Reduce False Alarms,” by Andrew Pollack, had me scratching my head. Had I missed something in the story of advances in prostate cancer screening … Continue reading
Posted in Prostate Cancer
Tagged false positives, Genomic Health, molecular markers, Myriad Genetics, PSA, screening, testing, treatment
Comments Off on With Prostate-Specific Antigen (PSA) Screening Questioned, Why Not Hurl Out the Next Unproven Prostate Tests?
What’s Next for Prostate Cancer Screening and Treatment?
Tweet Complex medical stories require time and energy to tell, talk about, and think about. When stories involve yanking a test or practice that is widely used, all hell breaks lose. That’s why I am grateful to appear today on … Continue reading
How Buffett’s Cancer is Shaping National Dialogue on Science Friday Today
Tweet I will be on Science Friday today, sometime between 3:30 and 4:00 PM EST, with Ira Flatow. In New York, it will be on WNYC, on KQED in San Francisco at their time for the show (a three-hour time … Continue reading
Posted in Prostate Cancer, Treatment decisions
Tagged active surveillance, KQED, men's health, radiation therapy, Science Friday, USPSTF, Warren Buffett, WNYC
5 Comments
Top 10 Reasons Why Warren Buffett’s Decision to Treat Prostate Cancer Bugs Me
Tweet On April 17th, 81-year-old Warren Buffett told investors that he had very early prostate cancer. The Washington Post headline read: “Warren Buffett Has Prostate Cancer that is ”Not Remotely Life Threatening.’” Within hours, news accounts said that the story … Continue reading
Terminology Matters: Let’s Not Call It “Prostate Cancer”
Tweet If ever there was a bombshell at a National Institutes of Health Consensus Development meeting, it happened today at the panel on active surveillance for prostate cancer. The Panel said that terminology matters and that men who have PSA … Continue reading